526 related articles for article (PubMed ID: 15573379)
1. Urokinase plasminogen activator receptor promotes macrophage infiltration into the vascular wall of ApoE deficient mice.
Gu JM; Johns A; Morser J; Dole WP; Greaves DR; Deng GG
J Cell Physiol; 2005 Jul; 204(1):73-82. PubMed ID: 15573379
[TBL] [Abstract][Full Text] [Related]
2. Mitogenic signaling of urokinase receptor-deficient kidney fibroblasts: actions of an alternative urokinase receptor and LDL receptor-related protein.
Zhang G; Cai X; López-Guisa JM; Collins SJ; Eddy AA
J Am Soc Nephrol; 2004 Aug; 15(8):2090-102. PubMed ID: 15284295
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
4. The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells.
Salasznyk RM; Zappala M; Zheng M; Yu L; Wilkins-Port C; McKeown-Longo PJ
Matrix Biol; 2007 Jun; 26(5):359-70. PubMed ID: 17344041
[TBL] [Abstract][Full Text] [Related]
5. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
6. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
7. Human urokinase-type plasminogen activator primes neutrophils for superoxide anion release. Possible roles of complement receptor type 3 and calcium.
Cao D; Mizukami IF; Garni-Wagner BA; Kindzelskii AL; Todd RF; Boxer LA; Petty HR
J Immunol; 1995 Feb; 154(4):1817-29. PubMed ID: 7836767
[TBL] [Abstract][Full Text] [Related]
8. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction.
Yebra M; Goretzki L; Pfeifer M; Mueller BM
Exp Cell Res; 1999 Jul; 250(1):231-40. PubMed ID: 10388537
[TBL] [Abstract][Full Text] [Related]
9. Urokinase-type plasminogen activator plays a critical role in angiotensin II-induced abdominal aortic aneurysm.
Deng GG; Martin-McNulty B; Sukovich DA; Freay A; Halks-Miller M; Thinnes T; Loskutoff DJ; Carmeliet P; Dole WP; Wang YX
Circ Res; 2003 Mar; 92(5):510-7. PubMed ID: 12600880
[TBL] [Abstract][Full Text] [Related]
10. Reduced beta3-endonexin levels are associated with enhanced urokinase-type plasminogen activator receptor expression in ApoE-/- mice.
Besta F; Müller I; Lorenz M; Massberg S; Bültmann A; Cabeza N; Richter T; Kremmer E; Nothdurfter C; Brand K; Gawaz M
Thromb Res; 2004; 114(4):283-92. PubMed ID: 15381392
[TBL] [Abstract][Full Text] [Related]
11. Vitronectin binding to urokinase receptor in human breast cancer.
Carriero MV; Del Vecchio S; Franco P; Potena MI; Chiaradonna F; Botti G; Stoppelli MP; Salvatore M
Clin Cancer Res; 1997 Aug; 3(8):1299-308. PubMed ID: 9815812
[TBL] [Abstract][Full Text] [Related]
12. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
Mohanam S; Chandrasekar N; Yanamandra N; Khawar S; Mirza F; Dinh DH; Olivero WC; Rao JS
Oncogene; 2002 Nov; 21(51):7824-30. PubMed ID: 12420219
[TBL] [Abstract][Full Text] [Related]
13. Urokinase-type plasminogen activator receptor reversibly dissociates from complement receptor type 3 (alpha M beta 2' CD11b/CD18) during neutrophil polarization.
Kindzelskii AL; Laska ZO; Todd RF; Petty HR
J Immunol; 1996 Jan; 156(1):297-309. PubMed ID: 8598477
[TBL] [Abstract][Full Text] [Related]
14. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
[TBL] [Abstract][Full Text] [Related]
15. Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrin.
Franco P; Vocca I; Carriero MV; Alfano D; Cito L; Longanesi-Cattani I; Grieco P; Ossowski L; Stoppelli MP
J Cell Sci; 2006 Aug; 119(Pt 16):3424-34. PubMed ID: 16882693
[TBL] [Abstract][Full Text] [Related]
16. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
Xue A; Xue M; Jackson C; Smith RC
Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of integrin alpha M beta 2 ligand-binding function by the urokinase-type plasminogen activator receptor.
Tang ML; Kong LS; Law SK; Tan SM
Biochem Biophys Res Commun; 2006 Sep; 348(3):1184-93. PubMed ID: 16905120
[TBL] [Abstract][Full Text] [Related]
18. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
Mamoune A; Kassis J; Kharait S; Kloeker S; Manos E; Jones DA; Wells A
Exp Cell Res; 2004 Sep; 299(1):91-100. PubMed ID: 15302576
[TBL] [Abstract][Full Text] [Related]
19. Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.
Rasch MG; Pass J; Illemann M; Høyer-Hansen G; Lund IK
J Immunol Methods; 2008 Nov; 339(1):55-65. PubMed ID: 18761343
[TBL] [Abstract][Full Text] [Related]
20. Urokinase plasminogen activator upregulates paraoxonase 2 expression in macrophages via an NADPH oxidase-dependent mechanism.
Fuhrman B; Khateeb J; Shiner M; Nitzan O; Karry R; Volkova N; Aviram M
Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1361-7. PubMed ID: 18436804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]